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BACKGROUND: Mounting evidence points to the efficacy of donor lymphocyte infusion (DLI) and immunisation with tumour-pulsed
dendritic cells (DC) in generating graft vs leukaemia reactions after allogeneic bone marrow transplantation (BMT). We assessed the
efficacy of DLI and DC in generating potent graft vs neuroblastoma tumour (GVT) reactions following allogeneic BMT.
METHODS: Mice bearing congenic (H2K
a) Neuro-2a tumours were grafted with allogeneic (H2K
b) T-cell-depleted bone marrow cells.
Tumour-pulsed donor DC (DC
Neuro2a) were inoculated (on day þ7) in conjunction with donor (H2K
b) and haploidentical (H2K
a/b)
lymphocytes.
RESULTS: Murine Neuro-2a cells elicit immune reactions as efficient as B lymphoma in major histocompatibility complex antigen-
disparate mice. Lymphopenia induced by conditioning facilitates GVT, and transition to adaptive immunity is enhanced
by simultaneous infusion of and DC
Neuro2a and lymphocytes devoid of graft vs host (GVH) activity (H2K
a/b). In variance, the
efficacy of DC-mediated immunomodulation was diminished by severe graft vs host disease (GVHD), showing mechanistic
dissociation and antagonising potential to GVT.
CONCLSIONS: The GVHD is not a prerequisite to induce GVT reactivity after allogeneic BMT, but is rather detrimental to induction of
anti-tumour immunity by DC-mediated immunomodulation. Simultaneous inoculation of tumour-pulsed donor DC and DLI synergise
in stimulation of potent GVT reactions to the extent of eradication of established NB tumours.
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Neuroblastoma (NB) is a low immunogenic solid tumour that
expresses low levels of major histocompatibility complex (MHC)
antigens and few known specific antigens, most of which
are shared with other tissues of ectodermal origin (Cooper et al,
1990; Coze et al, 1995; Prigione et al, 2004; Wolfl et al, 2005).
Considering the poor outcome of surgery and chemoradiotherapy
in paediatric patients with high-risk NB, immune-based therapeu-
tic approaches are being pursued (Verneris and Wagner, 2007;
Navid et al, 2009). For example, dendritic cells (DCs) are crucial
ingredients towards induction and propagation of tumour antigen-
specific immune reactions (Banchereau and Palucka, 2005),
endowed with the capacity to sensitise the immune system against
NB tumours ex vivo (Valteau-Couanet et al, 2002) and in vivo
(Geiger et al, 2000; Caruso et al, 2005). Bone marrow transplanta-
tion (BMT) evolves as a standard therapeutic procedure aiming
to maximise the efficacy and intensity of anti-tumour immunity
(Fish and Grupp, 2008; Ladenstein et al, 2008). Consequently,
immunomodulatory approaches have adopted to the transplant
setting, consisting either of vaccination with tumour-pulsed DC
(Asavaroengchai et al, 2002) or donor lymphocyte infusion (DLI)
under conditions of controlled graft vs host disease (GVHD,
Naparstek et al, 1996; Slavin, 2001).
Autologous BMT for immunohaematopietic reconstitution after
aggressive chemoradiotherapy have yielded modest results in the
absence of additional immunomodulation (Yaniv et al, 1990;
Kanold et al, 2000). The modest efficacy might be attributed to the
absence of graft vs tumour (GVT) reactions (Slavin et al, 2000),
which is more efficiently attained by allogeneic and haploidentical
BMT (Demirer et al, 2008; Kanold et al, 2008). Although allogeneic
BMT per se is endowed with the capacity to generate anti-tumour
immune reactivity (Ash et al, 2009), significant reduction and
eradication of even small-sized NB tumours requires substan-
tial post-transplant immunomodulation (Anderson et al, 2000;
Borrello et al, 2000; Teshima et al, 2001; Asavaroengchai et al,
2002). Accordingly, DCs have been efficiently implemented to
foster immunity against haematological malignancies after
allogeneic transplantation (Li and Waller, 2004; Reddy et al,
2005; Tatsuta et al, 2009). However, haematological malignancies
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scan elicit anti-tumour immunity through selective expression of
minor histocompatibility antigens (Riddell et al, 2002), which are
largely absent in solid tumours (Ringde ´n et al, 2009). In addition to
effective immunisation against solid tumours using tumour-pulsed
DC (Geiger et al, 2000; Caruso et al, 2005), recent evidence points
to the superior activity of DC after allogeneic BMT (Moyer et al,
2006). Successful ex vivo sensitisation and expansion of tumour-
reactive lymphocytes attribute DC a stimulatory effect (Xia et al,
2006; Ghosh et al, 2009), which can be achieved also by DLI
(Eto et al, 2008; Kamiryo et al, 2009; Yoshida et al, 2009).
Accordingly, the interaction between DC and lymphocytes
(Chakraverty et al, 2006) has been implemented in a number of
ways, including immunomodulation of the donors (Asavaroeng-
chai et al, 2004) and immunomodulation of the recipients (Li and
Waller, 2004; Moyer et al, 2006), although the relative roles of
host and donor DC in GVT and GVH reactions is under debate
(Shlomchik et al, 1999; Matte et al, 2004; Xia et al, 2006;
Chakraverty and Sykes, 2007).
These data indicate that cytotoxic lymphocytes are effectively
propagated by tumour-pulsed DC, with effective anti-leukaemia
effects attained by post-transplant administration of lymphocytes
and DC. Following the demonstration that tumour-pulsed donor
DC effectively suppress NB growth after allogeneic BMT (S Ash,
I Yaniv, N Askenasy, J Stein, unpublished data), it is questioned
whether their effect can be amplified by DLI to elicit potent GVT
reactions against this solid tumour. In variance from previous
studies aiming to decipher the mechanism of interaction between
antigen-presenting cells and lymphocytes (Shlomchik et al, 1999;
Li and Waller, 2004; Matte et al, 2004; Chakraverty et al, 2006; Xia
et al, 2006), we adopted a clinically relevant experimental model of
post-transplant immunomodulation of tumour bearing mice using
donor cells. We found that murine NB is an immunogenic tumour
submitted to immune surveillance after allogeneic BMT through
GVT reactivity that is independent of GVHD. Post-transplant
immunisation with tumour-pulsed antigen-presenting cell in
conjunction with lymphocytes devoid of GVH activity fosters
significantly GVT reactivity to the extent of eradication of
established tumours.
MATERIALS AND METHODS
Animal model
Mice used in this study were A/J (H2K
a, CD45.2), C57BL/6 (H2K
b,
CD45.2), B6.SJL-Ptprc
a Pepc
b/BoyJ (H2K
b, CD45.1), inbred
A:C57BL/6 F1 chimeras (H2K
a/b, CD45.2) and non-obese diabetic
/severe combined immunodeficiency (NOD/SCID) mice purchased
from Jackson Laboratories (Bar Harbor, ME, USA). Mice were
housed in a barrier facility in accordance with the guidelines of the
Institutional Animal Care and Use Committee.
Tumour cells
Neuro-2a cells murine NB (H2K
a) and A20 B-cell lymphoma
(H2K
d) were obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). Cells were cultured to maximum
12 passages as previously described (Ash et al, 2009). Subcuta-
neous tumours were induced by implantation of 10
6 Neuro-2a cells
in 100ml of phosphate-buffered saline (PBS). Tumour growth was
measured with a caliper and the volume (mm
3) was calculated
according to: (width
2 length 0.4).
Bone marrow cell preparation
Whole bone marrow cells (wBMCs) were harvested from the
femurs and tibia of donors, and low-density cells were collected as
previously described (Askenasy and Farkas, 2003). Immuno-
magnetic T-cell depletion was performed by incubating for 45min
at 41C with saturating amounts of biotinylated anti-mouse mono-
clonal antibodies (mAbs) specific to CD4, CD5 and CD8 (hybridoma
cell cultures, ATCC). The mAb-coated cells were washed twice with
PBS (Beit Haemek, Israel) containing 2% FCS (Biological Industries,
Beit Haemek, Israel) and were incubated with sheep-anti-rat IgG
conjugated to M-450 magnetic beads at a ratio of four beads per cell
(Dynal Inc., Lake Success, NY, USA). Conjugated cells were
precipitated by exposure to a magnetic field. The efficiency of
T-cell depletion was reassessed by flow cytometry using a cocktail of
primary labelled mAb against the T-cell markers listed above.
Splenocyte preparation
Spleens were harvested from mice, minced, passed through 40-mm
mesh and dispersed into single-cell suspensions in PBS (Kaminitz
et al, 2009). Red blood cells were lysed with medium containing
0.83% ammonium chloride, 0.1% potassium bicarbonate and
0.03% disodium EDTA. After 4min, the reaction was arrested with
excess of ice-cold PBS. T cells were enriched by elution through a
cotton wool column (preferential retention of B lymphocytes and
myeloid cells by differential charge than the eluted T cells), or
immunomagnetic depletion using hybridoma-derived antibodies
against GR-1, Mac-1 and B220 (ATCC). This procedure routinely
provides an enriched population of 70–80% T cells.
Dendritic cells
Mononuclear cells were harvested from bone marrow samples by
gradient centrifugation over murine Lympholyte (Cedarlane,
Burlington, Ontario, Canada) and cultured (10
6 cells per ml) in
low-LPS RPMI 1640 (o10pgml
–1) supplemented with 10% FBS,
1% L-glutamine, 1% sodium pyruvate, 1% a-MEM non-essential
amino acids, 0.1% Hepes buffer and 1% Pen/Strep (Biological
Industries; Gibco BRL, Grand Island, NY, USA; Sigma, St Louis,
MO, USA). The medium was supplemented with 50ngml
–1mouse
recombinant (mr) granulocyte macrophage colony-stimulating
factor (mrGM-CSF) and 10ngml
–1 interleukin-4 (mrIL-4) on
intermittent days (PeproTech, Rocky Hill, NJ, USA). Naı ¨ve DCs
were incubated for additional 24h in DC medium without growth
factors. Pulsing with tumour antigens was performed by
co-incubation of DC with tumour lysate at an approximate
DC/tumour cell ratio of 3:1 (Ash et al, 2009). Tumour lysate is
collected from the soluble fraction of Neuro-2a cells detached by
trypsin, after three cycles of freezing in liquid nitrogen (2min) and
thawing at 371C (4min) in PBS.
Conditioning and transplantation
Recipients were conditioned with total body irradiation at 700rad
using an X-ray irradiator (Rad Source 2000; Rad Source Tech-
nologies Inc., Alpharetta, GA, USA) at a rate of 106radmin
–1.
After 6h, cells were injected into the lateral tail vein in 200ml PBS.
Naı ¨ve and tumour-pulsed DCs were inoculated subcutaneously
adjacent to the tumour on day þ7 after transplantation, and
splenocytes were adoptively transferred intravenously.
Flow cytometry
Blood was collected in heparinised serum vials in 200ml M199,
centrifuged over 1.5ml lymphocyte separation media (Cedarlane),
and red blood cells were lysed. Nucleated cells were incubated for
45min at 41C with phycoerythrin (PE)-anti-H2K
b (Caltag,
Carlsbad, CA, USA) and fluorescein isothiocyanate (FITC)-anti-
H2K
k mAb cross-reactive with H2K
a (eBioscience, San Diego, CA,
USA). Minor antigen disparity was assed using CD45.1-PE and
CD45.2-FITC antibodies (eBioscience). T cells were quantified
using CD4-allophycocyanin and CD8-FITC antibodies (BD
Pharmingen, San Diego, CA, USA). Measurements were performed
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swith a Vantage SE flow cytometer (Becton Dickinson, Franklin
Lakes, NJ, USA). Positive staining was determined on a log scale,
normalised with control cells stained with isotype control mAb.
Histology
Skin and liver were collected from mice killed by CO2 asphyxia-
tion, and were fixed in ice-cold PBS containing 1.5% fresh
paraformaldehyde for 2h at 0–41C. Tissues were embedded in
OCT (Sakura Finetek, Torrance, CA, USA), frozen in isopentane
suspended in liquid nitrogen, sectioned (3–6mm) with a Cryotome
(Termo Shandon, Cheshire, UK) and stained with haematoxylin
and eosin.
GVH disease
Graft vs host disease was assessed using a semiquantitative clinical
scale including weight loss, posture (hyperkeratosis of the foot
pads impairs movement), activity, diffuse erythema (particularly
of the ear) or dermatitis, and diarrhoea. GVHD was validated by
histology in haematoxylin and eosin sections of the ear and liver
according to: 0 – no infiltration, 1 – scarce infiltrates, 2 – patchy
infiltration and 3 – diffuse infiltration with deterioration of tissue
structure. The modified score for the liver (Fukui et al, 2007) is
based on initial histological definition of GVHD pathology (Blazar
et al, 1993; Cooke et al, 1998).
Proliferation assays
Splenocytes were layered in plastic dishes for 45min and non-
adherent cells were labelled with 2.5mM 5-(and-6-)-carboxyfluorescein
diacetate succinimidyl ester (CFSE; Molecular Probes, Eugene, OR,
USA). Triplicate cultures were harvested after 3–5 days, evaluated for
CFSE dilution by flow cytometry and data were quantified using the
ModFit software (Verity SoftwareH o u s e ,T o p s h a m ,M E ,U S A ) .I n
some cases the cells were exposed to mitogenic stimulation with 5mM
concanavalin A (Biological Industries).
Cytotoxic assays
Effector splenocytes harvested from naı ¨ve mice and chimeras were
lysed and passed through wool mesh to enrich for T lymphocytes
(B70%). These cells were incubated with 5 10
5 Neuro-2a target
cells for 7h at 371C in 150ml at 1:10–1:100 target/effector ratios.
Cytolysis was quantified by lactate dehydrogenase (eBioscience)
release and normalised for background values.
Statistical analysis
Data are presented as means±s.d. for each experimental protocol.
Results in each experimental group were evaluated for reprodu-
cibility by linear regression of duplicate measurements. Differ-
ences between the experimental protocols were estimated with a
post hoc Scheffe t-test and significance was considered at Po0.05.
RESULTS
Immunogenicity of Neuro-2a cells
The Neuro-2a cell line is considered to be particularly low
immunogenic, as a general feature of human NB. To determine
the relative efficacy of tumour antigen presentation by Neuro-2a
cells, cytolytic responses were compared with the murine A20
lymphoma cell line. B6 mice (H2K
b) were immunised twice at
3-day interval, and lymphocytes were co-incubated with target
cells (Figure 1A). Neuro-2a cells (H2K
a) were gradually killed at
decreasing target/effector ratios and were comparable to lysis of
A20 (H2K
d, Figure 1B), with significant difference only at the
lowest target/effector ratio (Po0.05). Therefore, the Neuro-2a cell
line elicits effective immune responses comparable to an
immunogenic cell line (Asavaroengchai et al, 2002, 2004).
Lymphopenia is favourable to the induction of
GVT reactivity
Tumour growth in congenic mice is limited as compared with
immunocompromised mice, suggesting that Neuro-2a is submitted
to immune surveillance in immunocompetent mice (Ash et al,
2009). Furthermore, transition to adaptive immunity by either
syngeneic or allogeneic BMT suppressed tumour growth, suggest-
ing that a state of immune activation is beneficial to GVH
reactivity. To evaluate whether lymphopenia actually promotes
GVT reactivity (Borrello et al, 2000; Hu et al, 2002), tumour growth
in reconstituted NOD/SCID mice was compared with allogeneic
transplants (Figure 2A): mice were implanted with subcutaneous
tumours and after 5 days were conditioned and grafted with
5 10
6 allogeneic BMC. NOD/SCID mice were conditioned with
busulfan, which is significantly less immunosuppressive as
compared with total body irradiation (Askenasy and Farkas,
2003). Tumour growth was significantly suppressed by transplan-
tation of allogeneic whole BMC from H2K
a and K2K
b donors into
NOD/SCID mice (Po0.01, Figure 2B), consistent with avid
repopulation of the lymphopenic organs. Notably, residual host
immune cells are detected in lymphoid organs of allografted
immunocompetent mice after myeloablative irradiation (Kaminitz
et al, 2009), whereas in NOD/SCID mice the lymphoid organs were
full donor (not shown). Therefore, both intrinsic lymphopenia in
NOD/SCID mice and radiation-induced lymphodepletion facilitate
GVT reactivity.
Relationship between GVT and GVHD
Enhanced GVT reactivity under transplant-associated lympho-
penia questions whether immune reconstitution by DLI further
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Figure 1 Neuro-2a cells elicit immune reactions. (A) C57/BL mice
(H2K
b) were immunised with two intravenous injections of 3 10
6 Neuro-2a
(H2K
a) or A20 cells (H2K
d) at 3-day intervals and cytolytic responses were
evaluated after 3 days. (B) Target Neuro-2a (n¼6) and A20 cells (n¼5)
were exposed to lymphocytes from respectively immunised mice at various
target/effector ratios to determine lysis according to lactate dehydrogenase
(LDH) release. Data represent means±s.d.
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saugments anti-tumour immunity. We have recently observed
that early administration of donor DC reduces tumour growth
(S Ash, I Yaniv, N Askenasy, J Stein, unpublished data), whereas
infusion of F1 splenocytes alone neither affect Neuro-2a growth
in vivo nor induce GVHD as they are anergic to the host (Ash et al,
2009). The fast growth rates of Neuro-2a cells and the relatively fast
tempo of immune reconstitution in mice impose early post-
transplant immunomodulation in this experimental model. Mice
bearing subcutaneous tumours were grafted with allogeneic
(H2K
b-H2K
a) T-cell-depleted BMCs and on day þ7 were
inoculated with 10
6 donor DCs (subcutaneous) and 2 10
7 donor
(H2K
b) and F1 (H2K
a/b) splenocytes (intravenous, Figure 3A).
Whereas co-administration of donor lymphocytes resulted in
higher tumour sizes as compared with DC alone (Po0.05,
Figure 3B), F1 lymphocytes suppressed tumour growth (Po0.01
vs DC alone), resulting in remarkable superior efficacy of F1-DLI
(Po0.005 vs allogeneic DLI). Furthermore, early allogeneic DLI
induced high-grade GVHD (Po0.001, Figure 3C) accompanied by
weight loss (Po0.001, Figure 3D), whereas F1 splenocytes were
devoid of GVHD activity. These data dissociate the mechanisms of
GVT and GVHD, emphasising that GVHD rather impairs the
efficacy of GVT reactions.
Donor DC present antigens in the context of compatible MHC to
both allogeneic (H2K
b) and haploidentical splenocytes (H2K
a/b).
The stimulatory effect of DC was evident from marked prolif-
erative responses of lymphocytes to mitogenic stimulation at the
experimental end point (4 weeks after BMT). Inoculation of
tumour-pulsed DC alone enhanced the cycling rates of donor
lymphocytes derived from the bone marrow of the chimeras, with a
less accentuated effect after simultaneous administration of DC
and F1 lymphocytes (Po0.05, Figure 3E). Importantly, in vitro
rechallenge with naı ¨ve and tumour-pulsed DC generated strong
proliferation (Po0.005 vs lymphocytes alone), emphasising
effective DC-mediated immune activation in vivo as a basis for
tumour growth suppression.
Consequences of DLI and DC administration
Given that the combination of F1 lymphocytes and DC suppressed
tumour growth, we reasoned that fostering immune reconstitution
by adoptive transfer of lymphocytes at the time of transplantation
might provide additional benefit (Figure 4A). Sequential admin-
istration of F1 lymphocytes (day 0) and donor DC (day þ7)
conferred no significant inhibition of tumour growth (Figure 4B).
Consistent with simultaneous administration of lymphocytes and
DC (Figure 3E), proliferative responses were decreased by F1
lymphocyte infusion at the time of transplantation (Po0.05 vs DC
alone, Figure 4C), and responsiveness was markedly increased by
in vitro rechallenge with DC (Po0.005). Thus, DC administration
has a stimulatory effect over lymphoid reconstitution; however,
adoptive transfer of F1 lymphocytes in conjunction with BMCs
does not suppress tumour growth.
Reduced proliferation of splenocytes in recipients of F1
lymphocytes might be attributed either to the timing of adoptive
transfer or variable interactions with the DC. These possib-
ilities were analysed by monitoring the immune profiles of
the reconstituted mice. Quantitatively, spleen cellularity at the
experimental end point of 4 weeks was reduced by F1 lymphocyte
infusion (day 0) and was apparently unaffected by F1 lymphocyte
infusion on day þ7 (Figure 5A). Qualitatively, minor differences
in splenic T-cell subsets were observed under the different
treatment protocols (Figure 5B), with a trend of reduced T-cell
fraction in mice infused with DC
Neuro2a. As F1 lymphocytes are not
detected in the lymphoid organs of recipients at 4 weeks after
transplantation (Ash et al, 2009), transient engraftment might
modulate lymphoid reconstitution by cells derived from the bone
marrow. Administration of F1 splenocytes on day 0 resulted in
transient rise in spleen cellularity that subsided during the third
week, whereas infusion of F1 splenocytes on day þ7 caused a
more sustained rise in spleen cellularity (Figure 5C). These
differences correlate with the slower growth rates of tumours
attained by F1 lymphocyte infusion on day þ7 as compared with
day 0, showing that the kinetics of lymphoid reconstitution are
important to maximise the maturing effect of DC.
Efficacy of post-transplant immunomodulation
The relative efficacy of the various protocols was determined by
tumour size at the experimental end point and eradication of
established tumours (460mm
3). Although tumour-pulsed DC
suppressed the growth of Neuro-2a cells under all conditions
(Po0.01, Figure 6A), adoptive transfer of F1 splenocytes alone
had no significant impact. The only additive effect was obtained
by joint administration of F1 splenocytes and DC
Neuro2a on
day þ7( Po0.01 vs DC alone, Po0.001 vs F1 splenocytes alone).
Consistently, the profile of complete regression of tumours
exceeding 60mm
3 mirrored the variations in tumour size
(Figure 6B), reinforcing the validity of growth measurements.
Notably, the experimental conditions were designed to maximise
differences between the various experimental conditions by
generating relatively large tumours. Therefore, the important
component towards induction of effective GVT constitutes of
donor DC infusion, which elicits potent reactions able to cause
complete regression of established tumours.
DISCUSSION
Neuroblastoma is a potential target of GVT reactivity attained by
allogeneic BMT and subsequent immunomodulation. Murine NB
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Figure 2 Tumour growth in congenic and immunocompromised mice.
(A) Mice were implanted with subcutaneous Neuro-2a cells and after
5 days were conditioned and grafted with 5 10
6 whole bone marrow
cells (BMCs). Immunocompetent mice were irradiated (700rad) and
immunocompromised non-obese diabetic/severe combined immuno-
deficiency (NOD/SCID) mice were conditioned with busulfan
(2 25mgg
–1). (B) Tumour growth in allografted mice congenic to the
tumour (H2K
a, n¼19) and NOD/SCID mice (H2K
g7) grafted with whole
BMCs from B6 (H2K
b, n¼9) and A (H2K
a, n¼7) donors.
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sexpresses MHC class II antigens (Ash et al, 2009) and elicits
immune responses as efficient as A20 lymphoma in MHC-
disparate mice (Asavaroengchai et al, 2002). However, effective
GVT reactivity is mediated by cytotoxic cells derived from the
bone marrow that are anergic to host MHC, indicating that tumour
associated antigens are the primary targets of this reaction.
Recruitment of lymphocytes reactive against the tumour is
important in view of the low level expression of MHC antigens
in human NB (Wolfl et al, 2005).
Transplant procedures associated with lymphopenia are gen-
erally associated with increased susceptibility to development of
GVT reactions (Borrello et al, 2000; Hu et al, 2002). Our current
data are consistent with the permissive effect of syngeneic and
allogeneic BMT to evolution of anti-tumour immunity (Wrzesinski
and Restifo, 2005), and the anti-tumoural activity of syngeneic
transplants preceding implantation of tumours (Ash et al, 2009).
In this study, we further demonstrate that the strain congenic
to the tumour is not immunodeficient, as reconstitution of
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Figure 3 Adoptive transfer of dendritic cells (DCs) and lymphocytes in allografted mice bearing tumours. (A) Experimental design of 5 10
6 allogeneic
(H2K
b-H2K
a) T-cell-depleted bone marrow cell (TCD-BMC) transplantation into irradiated (700rad) mice implanted with subcutaneous tumours 5 days
earlier. On day þ7 the mice were inoculated subcutaneously with tumour-pulsed DC (DC
Neuro2a) in conjunction with intravenous infusion of 2 10
7
donor (H2K
b) or F1 (H2K
a/b) splenocytes (spln.). (B) Tumour growth in allografted mice (n¼19), recipients of DC
Neuro2a alone (n¼17) and in conjunction
with allogeneic (n¼6) or F1 splenocytes (n¼11). (C) Histological scoring of inflammatory infiltrates in ear wedge biopsies and livers of recipients of donor
and F1 splenocytes. (D) Percent changes in body weight of recipients of allogeneic and F1 splenocytes. (E) Proliferation index of splenocytes upon mitogenic
activation with concanavalin A (ConA) in vitro and rechallenge with naı ¨ve (DC
Naive) and tumour-pulsed DC (DC
Neuro2a): allografted mice (allogeneic bone
marrow transplantation (allo-BMT)), recipients of F1 splenocytes alone (F1 spln.), recipients of tumour-pulsed DC (DC
Neuro2a) alone and in conjunction with
F1 splenocytes (n¼6 in each group).
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sNOD/SCID mice impairs tumour growth as efficient as C57BL/6
donors. Effective tumour suppression upon transition to adaptive
immunity by BMT might be particularly significant to the
treatment of NB. This tumour develops in the prenatal phase
from ectodermal origin (Coze et al, 1995; Prigione et al, 2004;
Wolfl et al, 2005), and is therefore actively shielded by suppressive
elements of innate immunity. This suppression is removed
not only by pre-transplant conditioning, which is common to
syngeneic and allogeneic transplants, but by the emerging
GVT reactivity that develops during immunohaematopoietic
reconstitution. Radiochemotherapy also inflicts direct injury to
the tumour, facilitating selective sensitisation of the recovering
immune system against tumour antigens (Asavaroengchai et al,
2002; Cho et al, 2000).
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6 T-cell-depleted bone marrow cells (TCD-BMCs)
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sProfessional processing and presentation of tumour antigens
by DC elicits anti-tumour reactivity and causes complete regres-
sion of established NB tumours. Antigen-specific responsiveness is
demonstrated by vigorous proliferative responses of lymphocytes
upon rechallenge with tumour-pulsed DC in vitro. These data
corroborate previous reports of potent vaccination following
syngeneic BMT (Borrello et al, 2000; Asavaroengchai et al, 2002)
achieved by tumour cells engineered to express co-stimulatory
molecules (Jing et al, 2007) and cytokines (Bausero et al, 1995),
and overexpression of cytokines in DCs (Tatsuta et al, 2009).
A remarkable feature of DC-mediated tumour suppression was
their efficacy at very low levels of T cells, reaching one-third of the
steady state conditions at the experimental end point. Consistent
with participation of DC in maturation of the developing
immune system, the quantitative deficit was compensated by
pronounced responses to antigens characteristic of lymphopenic
mice as compared with T-cell-sufficient mice (Cho et al, 2000;
Asavaroengchai et al, 2002; Shklovskaya and Fazekas, 2006).
In contrast to our initial assumption that early reinforcement of
lymphoid reconstitution at the time of transplantation will favour
GVT reactivity, simultaneous administration of F1 lymphocytes
and donor DC converged to suppress tumour growth. This
differential behaviour reflects distinct mechanisms of action, given
that F1 lymphocytes engraft transiently and are undetected at 4
weeks after transplantation (Ash et al, 2009). Infusion of F1
lymphocytes at the time of BMT impaired spleen repopulation,
likely through competitive homoeostatic expansion with
BM-derived lymphocytes in peripheral lymphoid organs (Teshima
et al, 2001; Zo ¨ller, 2003). In variance, immune activation by donor
DC was fostered by F1 lymphocytes, cells endowed with cytotoxic
activity against Neuro-2a cells (S Ash, I Yaniv, N Askenasy, J Stein,
unpublished data). Therefore, transient lymphoid support con-
ferred by DLI is beneficial to the generation of anti-tumour
immunity, but the optimal timing of administration is significant
(Chakraverty et al, 2006). Lymphocyte infusion appears to be
necessary in the context of syngeneic BMT (Jing et al, 2009),
whereas, in allogeneic transplants, DLI can have both positive and
detrimental consequences. Although we applied immunomodula-
tion early after transplantation, the toxicity of DLI is generally
reduced when administered at later times (Eto et al, 2008;
Prigozhina et al, 2008). Unlike the contention of reduced DC
capacity to stimulate mature lymphocytes as compared with cells
developing from the bone marrow (Feuerer et al, 2001), our data
demonstrate effective transient stimulation of mature F1 lympho-
cytes despite dominance of the bone marrow in immune
reconstitution (Ash et al, 2009). A transient beneficial effect of
DLI has been recently documented in a case report in which
infusion of ex vivo expanded donor CD4
þ T cells mediated
reactivity against disseminated recurrent NB (Yoshida et al, 2009).
Effective GVT reactivity attained by transplantation of allo-
geneic T-cell-depleted BMC is dissociated from the detrimental
GVH disease (Anderson et al, 2000; Teshima et al, 2001; Lang et al,
2006; Ash et al, 2009). In our hands donor DC did not inflict
GVHD, although their potential to enhance anti-host reactivity of
immature bone marrow-derived lymphocytes and mature haplo-
identical (F1) lymphocytes has been demonstrated (Li and Waller,
2004; Matte et al, 2004; Banchereau and Palucka, 2005). Both GVT
and GVH reactions are also effectively triggered by host DC
(Shlomchik et al, 1999) and in conjunction with DLI (Chakraverty
et al, 2006; Xia et al, 2006). Our data demonstrate that the tumour-
suppressive reaction induced by donor DC was impaired by
ongoing GVHD, suggesting little mechanistic association between
these reactions. The GVHD is mediated primarily by mature donor
lymphocytes that target minor tissue antigens (Ringde ´n et al,
2009), with severe toxicity in haploidentical transplants because
the effectors are not rejected. It is therefore possible to dissociate
between GVHD and therapeutic GVT, which is effectively attained
through tumour-specific attack by host MHC-tolerant lympho-
cytes. Haploidentical TCD-BMT might be of benefit as a maximal
possible mismatch for stimulation of the developing immune cells
against malignant tissue, a clinically feasible approach when
mature GVH effectors are eliminated form the donor inoculum,
which can be achieved also in delayed DLI (Eto et al, 2008;
Prigozhina et al, 2008; Bohana-Kashtan et al, 2009). The efficacy of
host and donor DC in promoting the GVT reaction without
imposing GVHD (Li and Waller, 2004; Chakraverty et al, 2006; Xia
et al, 2006; Ghosh et al, 2009) suggest that non-myeloablative
transplants might be equally and even more effective in generating
anti-tumour immunity (Slavin et al, 2000).
In summary, NB is a solid tumour effectively attacked by
immune reactions, which can be reinforced by post-transplant
immunomodulation. As BMT becomes a standard procedure in
high-risk patients, allogeneic transplants have the significant
advantage of generating potent GVT reactions. Anti-tumour
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Figure 6 Dendritic cells (DCs) enhance GVT reactivity. (A) Tumour size
on day 28 after transplantation of allogeneic T-cell-depleted bone marrow
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day þ7 and intravenous adoptive transfer of F1 splenocytes (spln.).
(B) Complete regression of established tumours (460mm
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after transplantation under conditions of partial reconstitution of
the T-cell compartment without causing GVHD, and can be
augmented by DLI. These synergistic measures are significant in
the competition against an aggressive and fast growing tumour
such as NB, underlining the importance of optimisation of the
details of the transplant procedure.
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